

RESEARCH ARTICLE

Investigation of Homocysteine, Vitamin B₆ and Vitamin D among Patients with Colorectal Cancer

Fenik A. Nadir¹, Zeyan A. Ali²

^{1,2}Department of Chemistry, College of Education, Salahaddin university-Erbil, Iraq

*Corresponding author:

Fenik A. Nadir,
Department of Chemistry,
College of Education,
Salahaddin university-
Erbil, Iraq.

E-mail:

fenik.nadir@su.edu.
irk

Received: 28 August 2022

Accepted: 11 October 2022

Published: 1 February 2023

DOI

10.25156/pj.v12n1y2022.pp168-173

ABSTRACT

Background and objectives: Colorectal cancer (CRC) is a disease that begins exclusively in the colon or rectum and is caused by the abnormal growth of glandular epithelial cells within the colon. Homocysteine, vitamin B₆, and vitamin D are recognized to play a significant role in colorectal tumor pathogenesis. The aim of this study to investigate serum levels of Hcy, vitamin D and vitamin B₆ in colorectal cancer.

Methods: The current study investigated the vital roles of homocysteine, vitamin B₆ and vitamin D in cancer development by comparing serum levels of colorectal cancer patients with those of the healthy control group at Nanakaly hospital. The levels of serum homocysteine (Hcy), vitamin B₆ and vitamin D in 50 colorectal cancer patients and 50 from the healthy control group have been examined.

Results: The result shows significantly high values of serum homocysteine ($p < 0.0001$) and significant decreases in values of vitamin B₆ and vitamin D ($p < 0.0001$ and 0.0010) respectively, in patients with CRC when compared with the healthy group.

Conclusions: Our findings demonstrate that increased levels of homocysteine and decreased levels of vitamin B₆ and vitamin D could be associated with the pathogenesis and progression of colorectal cancer.

Key Words: Homocysteine, vitamin B₆, Vitamin D, Colorectal cancer

INTRODUCTION

Colorectal cancer (CRC) is the third most common type of cancer diagnosed. It is the second most frequent cancer in men, after prostatic adenocarcinoma, and the third most prevalent cancer in women, after breast adenocarcinoma (Torre et al., 2015, Ferlay et al., 2019, Morimoto et al., 2022). According to the latest Global Cancer Statistics report, in 2020 there will be roughly 2 million new cases of CRC and 935,000 fatalities (Sung et al., 2021). CRC is becoming an increasingly significant public health issue, particularly in wealthy countries (Arem et al., 2013). In prospective epidemiologic studies, markers of obesity, inflammation, and diabetes were connected to an increased risk of CRC (Tarasiuk et al., 2018).

Homocysteine (Hcy), an amino acid containing sulfur, is generated as a metabolic intermediate by many cells in the body as a yield of demethylation during the metabolism of methionine. Plasma levels of Hcy are controlled by genetic variations of its major metabolic enzymes (Phelip et al., 2008, Mühl et al., 2022). Methylenetetrahydrofolate reductase is a critical enzyme in Hcy metabolism, regulating intracellular folate pools for the production and methylation of

deoxyribonucleic acid. Vitamins B₆, Vitamin B₉, and B₁₂, are essential for the chemical processes required for the breakdown of Hcy. Elevated total homocysteine may serve as an important indicator of cancer and a sensitive indicator of recurrence. The correlation between serum levels of homocysteine and several carcinogenesis markers in breast, colon, and pancreatic cancers suggests that total serum Hcy levels, such as malignancy markers, indicate the activity of cancer cells or the rate of fast proliferation of malignancy cells (Mendonça et al., 2018). In addition, cell tissue culture research indicated that the growth of tumor cells causes hyperhomocysteinemia (Keshteli et al., 2015, Mühl et al., 2022).

Vitamin B₆ (Vit.B₆) or pyridoxine is a water-soluble vitamin that is crucial for cellular metabolism in general (Hellmann and Mooney, 2010). Pyridoxal 5-phosphate (PLP), the active form of vitamin B₆, is provided as a co-factor in over 150 enzymatic reactions that act as catalysts in important metabolic reactions, such as production, transformation, and destruction of amino acids, production of one carbon unit, trans-sulfuration, formation of tetrapyrrolic substances and polyamines, biosynthesis, and degradation of neuro-transmitters (Di Salvo et al., 2011). Vitamin B₆ can neutralize oxygen reactive species (ROS) while not being classified as a typical antioxidant (Mascolo and Verni, 2020). Additionally, vitamin B₆ inhibits

angiogenesis, lowers nitric oxide, and decreases oxidative stress, all of which are associated with suppressing tumorigenesis. Decreased vitamin B₆ levels may also be connected with chronic inflammation, a potentially colon cancer risk factor, depending on the significantly lower PLP levels found in patients with rheumatoid arthritis and inflammatory bowel disease (IBD) in comparison to the general population (Zhang et al., 2013, Gylling et al., 2017).

Vitamin D (Vit.D), a fat-soluble vitamin that can be generated in the skin by the sun's radiation or taken through food or supplementation. The liver converts both vitamin D isoforms, which are obtained through diet, supplements, or skin production, into 25(OH)D, the main form of vitamin D that circulates in the body. A 25(OH)D blood test is considered the most accurate predictor of vitamin D levels for a variety of outcomes, including the development of carcinoma (Hernández-Alonso et al., 2021). The high incidence of CRC is closely related to Vit.D deficiency, and Vit.D supplements can prevent the onset and progression of colorectal malignancy (Vaughan-Shaw et al., 2020). Additionally, vitamin D contributes to reversing colorectal cancer primarily by regulating intestinal flora, particularly Akkermansia muciniphila-mediated colon barrier integrity (Zhou et al., 2020). Therefore, this study aimed to investigate the serum Hcy, vitamin B₆, and vitamin D levels and its correlation in CRC patients, to find out its association with the CRC pathogenesis and developing.

Materials and Methods

The investigation was conducted on fifty patients between July 2021 and January 2022; their ages ranged from 29 to 65 years at stages III and IV after taking the first and second chemotherapy doses. The work was performed at the Nanakaly hospital in the governorate of Erbil. In addition, samples were taken from fifty healthy volunteers (as determined by health professionals) and their analytical data was contributed to our study as age-specific control groups (28–65). Randomizations were considered during sample selection. Throughout the study period, blood samples have been drawn from the cubital vein at varying times. The samples were centrifuged to extract the serum, which was then analyzed for Hcy, vitamin B₆ and vitamin D levels.

Measurements of serum Hcy, vitamin B₆ and vitamin D

The serum was separated by centrifugation and placed in a cooler at a low temperature. The homocysteine and vitamin B₆ serum concentrations of the cancer and control groups were then assessed using ELISA (Enzyme-Linked Immunosorbent Assay), and the vitamin D serum concentration was determined using Statlab T. The ELISA reader (ELISA reader BioTek TS 800) measurements at 450 nm for Hcy and vitamin B₆ and Statlab T measurements at 700 nm for vitamin D elicited the analytical results from the human ELISA kit. The

concentration of Hcy in the examined samples was reported in $\mu\text{mol/L}$, while the concentrations of vitamin B₆ and vitamin D were expressed in ng/mL .

Statistical analysis

GraphPad Prism 9.0 was used to perform the statistical analysis. The data is presented as the Mean \pm SEM. The T-test was used to evaluate the comparison between the two groups. Two-sided P values were used, and significance differences were assumed to be less than $P < 0.05$.

Results and Discussion

The study population was 100 subjects, and all subjects were divided into two main groups (patients and healthy subjects) as illustrated in (Table 1 and Fig.1). Table 1 presents the results of three parameters (Hcy, Vit.B₆, and Vit.D) from the serum of patients and normal controls. There was a statistically significant increase in Hcy ($69.83 \pm 2.276 \mu\text{mol/L}$), and a significant decrease in Vit.B₆, and Vit.D (0.2664 ± 0.03301 and $22.43 \pm 1.945 \text{ ng/mL}$) respectively in the mean level of cases with CRC when compared to healthy group (7.295 ± 0.3939 , 5.617 ± 0.6904 , and 34.21 ± 2.850) respectively.

Table 1: Serum levels of Hcy, Vit.B₆, and Vit. D in patients with healthy control

Serum parameters	Control	CRC patient	P-value
Hcy ($\mu\text{mol/L}$)	7.295 ± 0.3939	69.83 ± 2.276	< 0.0001
Vitamin B ₆ (ng/mL)	5.617 ± 0.6904	0.2664 ± 0.03301	< 0.0001
Vitamin D (ng/mL)	34.21 ± 2.850	22.43 ± 1.945	0.0010




Fig. 1: Serum Hcy level in the patients with CRC and healthy control group

Homocysteine is an intermediate compound needed in the trans-sulfuration process that produces cysteine from methionine. Methionine synthase (MTR) is encoded by the MTR gene and catalyzes the remethylation of homocysteine to methionine to keep up adequate intercellular folate levels, required for deoxyribonucleic acid synthesis, methylation, and homeostasis (Lissowska et al., 2007). Our data findings are consistent with previous studies by numerous researchers from various countries, which showed that patients with colorectal cancer had significantly elevated total serum homocysteine levels (Miller et al., 2013, Liu et al., 2018, Mühl et al., 2022).

The increasing release of homocysteine into the plasma of colorectal cancer patients may be a result of reduced metabolic activity, poor nutrition, or deficient absorption, especially of folic acid, which impacts the methionine cycle. Additionally, due to the rapid growth of tumor cells, more folic acid and Vit.B₁₂ may be taken, resulting in decreased concentrations of folate and vitamin B₁₂, which further impacts the metabolism of Hcy and raises levels of homocysteine in plasma (Figueiredo et al., 2009).

The same table (Table 1) and Fig. (2) show the levels of vitamin B₆ of the CRC patients and normal group. The mean \pm standard error of CRC was (0.2664 \pm 0.03301 ng/ml), whereas in the control group it was (5.617 \pm 0.6904 ng/ml). These results have shown that CRC patients had a lower serum vitamin B₆ level than the normal groups, and there were significant differences between the CRC patients and normal subjects ($p < 0.0001$). Our results were in accordance with the data from other studies showing that mean vitamin B₆ levels decrease in those with colorectal carcinoma in comparison to normal individuals (Jia et al., 2017). Pyridoxine could play a crucial role in CRC progression. Decreases in vitamin B₆ levels raise the risk of CRC. It could be according to one-carbon metabolism, which includes the transfer of one-carbon groups for synthesis and deoxyribonucleic acid methylation. A deficiency in vitamin B₆ has been linked to a significantly altered one-carbon metabolic pathway. (Larsson et al., 2010, Zhang et al., 2013). Vitamin B₆ may also inhibit CRC by lowering angiogenesis, cell proliferation, nitric oxide synthesis, oxidative stress, and inflammation (Larsson et al., 2010).




Fig.2: Serum vitamin B₆ level in the patient with CRC and healthy control group

Another parameter which considered in those CRC patients is Vitamin D. The total serum level of vitamin D is shown in (Table 1 and Fig. 3) for both groups, and the concentration of vitamin D in CRC patients and control subjects was (22.43 \pm 1.945 ng/mL) and (34.21 \pm 2.850) respectively. In this study, our results have shown that CRC patients had a lower serum vitamin D level than healthy controls. This result was agreement with other studies showing that concentration of vitamin D decreased in patients with colorectal carcinoma than in the healthy control group (Huang et al., 2020, Boughanem et al., 2021). The modulation of the immune response is one of the major significant functions of vitamin D (Chun et al., 2014, Medrano et al., 2018). This involves supporting cells of the host immune response, such as monocytes and dendritic cells, to defend against infection by bacteria such as tuberculosis (TB). In addition, Vit.D reduces overreactions of adaptive immune system cells, such as T cell activation, which can lead to autoimmune disorders like varied IBD or sclerosis (Dankers et al., 2017, Lu et al., 2019). In contrast, those with IBD and low Vitamin D have a dramatically elevated risk of CRC development (Ananthakrishnan et al., 2014). Preclinical research supports the role of Vit.D in tumor prevention by exerting anti-proliferative, pro-apoptotic, anti-invasion, anti-angiogenic, anti-metastatic, and anti-inflammatory actions on cancer cells (Feldman et al., 2014). The decrease of Vitamin D progresses in major chronic diseases, including various types of malignancies (Mühl et al., 2022). Figs. 4A, B, and C display the ROC curve for CRC detection based on Hcy, vitamin B₆, and vitamin D quantification (50 CRC cases compared with 50 control subjects). A relatively high AUC (area under the curve) suggests that testing for Hcy, vitamin B₆ and Vit.D could be helpful in CRC detection.




Fig. 3: Serum vitamin D level in the patient with CRC and healthy control group

Fig. 4B: The ROC curve of vitamin B₆




Figure 4C: The ROC curve of vitamin D





Fig. 4A: The ROC curve of Hcy



The correlation between Hcy and vitamin B₆ showed there was a negative correlation (0.04161), which was statistically non-significant (Fig.5). Also, the correlation between Hcy and vitamin D showed there was a positive correlation ($r=0.0054$), which was statistically non-significant (Fig.6).




Fig. 5: correlation between Hcy and vitamin B₆




Fig. 6: Correlation between Hcy and vitamin D

Conclusions

The results of the present study indicate that homocysteine, pyridoxine and vitamin D levels in the serum of colorectal carcinoma patients differed significantly from those of randomly selected healthy controls. Therefore, these parameters play a crucial role in colorectal carcinoma progression and can be used as biomarkers for CRC.

Acknowledgement

The authors extend a special and wide thanks to Mrs. Shayma Ahmed at the College of Education for her help.

REFERENCES

- ANANTHAKRISHNAN, A. N., CHENG, S. C., CAI, T., CAGAN, A., GAINER, V. S., SZOLOVITS, P., SHAW, S. Y., CHURCHILL, S., KARLSON, E. W. & MURPHY, S. N. 2014. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. *Clinical Gastroenterology and Hepatology*, 12, 821-827.
- AREM, H., MAYNE, S. T., SAMPSON, J., RISCH, H. & STOLZENBERG-SOLOMON, R. Z. 2013. Dietary fat intake and risk of pancreatic cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *Annals of epidemiology*, 23, 571-575.
- BOUGHANEM, H., CANUDAS, S., HERNANDEZ-ALONSO, P., BECERRA-TOMÁS, N., BABIO, N., SALAS-SALVADÓ, J. & MACIAS-GONZALEZ, M. 2021. Vitamin D intake and the risk of colorectal cancer: an updated meta-analysis and systematic review of case-control and prospective cohort studies. *Cancers*, 13, 2814.
- CHUN, R. F., LIU, P. T., MODLIN, R. L., ADAMS, J. S. & HEWISON, M. 2014. Impact of vitamin D on

immune function: lessons learned from genome-wide analysis. *Frontiers in physiology*, 5, 151.

- DANKERS, W., COLIN, E. M., VAN HAMBURG, J. P. & LUBBERTS, E. 2017. Vitamin D in autoimmunity: molecular mechanisms and therapeutic potential. *Frontiers in immunology*, 697.
- DI SALVO, M. L., CONTESTABILE, R. & SAFO, M. K. 2011. Vitamin B6 salvage enzymes: mechanism, structure and regulation. *Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics*, 1814, 1597-1608.
- FELDMAN, D., KRISHNAN, A. V., SWAMI, S., GIOVANNUCCI, E. & FELDMAN, B. J. 2014. The role of vitamin D in reducing cancer risk and progression. *Nature reviews cancer*, 14, 342-357.
- FERLAY, J., COLOMBET, M., SOERJOMATARAM, I., MATHERS, C., PARKIN, D. M., PIÑEROS, M., ZNAOR, A. & BRAY, F. 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *International journal of cancer*, 144, 1941-1953.
- FIGUEIREDO, J. C., GRAU, M. V., HAILE, R. W., SANDLER, R. S., SUMMERS, R. W., BRESALIER, R. S., BURKE, C. A., MCKEOWN-EYSEN, G. E. & BARON, J. A. 2009. Folic acid and risk of prostate cancer: results from a randomized clinical trial. *Journal of the National Cancer Institute*, 101, 432-435.
- GYLLING, B., MYTE, R., SCHNEEDE, J., HALLMANS, G., HÄGGSTRÖM, J., JOHANSSON, I., ULVIK, A., UELAND, P. M., VAN GUELPEN, B. & PALMQVIST, R. 2017. Vitamin B-6 and colorectal cancer risk: a prospective population-based study using 3 distinct plasma markers of vitamin B-6 status. *The American Journal of Clinical Nutrition*, 105, 897-904.
- HELLMANN, H. & MOONEY, S. 2010. Vitamin B6: a molecule for human health? *Molecules*, 15, 442-459.
- HERNÁNDEZ-ALONSO, P., BOUGHANEM, H., CANUDAS, S., BECERRA-TOMÁS, N., FERNÁNDEZ DE LA PUENTE, M., BABIO, N., MACIAS-GONZALEZ, M. & SALAS-SALVADÓ, J. 2021. Circulating vitamin D levels and colorectal cancer risk: A meta-analysis and systematic review of case-control and prospective cohort studies. *Critical Reviews in Food Science and Nutrition*, 1-17.
- HUANG, D., LEI, S., WU, Y., WENG, M., ZHOU, Y., XU, J., XIA, D., XU, E., LAI, M. & ZHANG, H. 2020. Additively protective effects of vitamin D and calcium against colorectal adenoma incidence, malignant transformation and progression: A systematic review and meta-analysis. *Clinical Nutrition*, 39, 2525-2538.
- JIA, K., WANG, R. & TIAN, J. 2017. Vitamin B6 intake

- and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. *Nutrition and cancer*, 69, 723-731.
- KESHTELI, A. H., BARACOS, V. E. & MADSEN, K. L. 2015. Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review. *World Journal of Gastroenterology: WJG*, 21, 1081.
- LARSSON, S. C., ORSINI, N. & WOLK, A. 2010. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. *Jama*, 303, 1077-1083.
- LISSOWSKA, J., GAUDET, M. M., BRINTON, L. A., CHANOCK, S. J., PEPLONSKA, B., WELCH, R., ZATONSKI, W., SZESZENIA-DABROWSKA, N., PARK, S. & SHERMAN, M. 2007. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: A population-based case-control study and meta-analyses. *International journal of cancer*, 120, 2696-2703.
- LIU, Z., CUI, C., WANG, X., FERNANDEZ-ESCOBAR, A., WU, Q., XU, K., MAO, J., JIN, M. & WANG, K. 2018. Plasma levels of homocysteine and the occurrence and progression of rectal cancer. *Medical science monitor: international medical journal of experimental and clinical research*, 24, 1776.
- LU, M., MCCOMISH, B. J., BURDON, K. P., TAYLOR, B. V. & KÖRNER, H. 2019. The association between vitamin D and multiple sclerosis risk: 1, 25 (OH) 2D3 induces super-enhancers bound by VDR. *Frontiers in immunology*, 10, 488.
- MASCOLO, E. & VERNÌ, F. 2020. Vitamin B6 and diabetes: relationship and molecular mechanisms. *International journal of molecular sciences*, 21, 3669.
- MEDRANO, M., CARRILLO-CRUZ, E., MONTERO, I. & PEREZ-SIMON, J. A. 2018. Vitamin D: effect on haematopoiesis and immune system and clinical applications. *International journal of molecular sciences*, 19, 2663.
- MENDONÇA, N., JAGGER, C., GRANIC, A., MARTIN-RUIZ, C., MATHERS, J. C., SEAL, C. J. & HILL, T. R. 2018. Elevated total homocysteine in all participants and plasma vitamin B12 concentrations in women are associated with all-cause and cardiovascular mortality in the very old: the Newcastle 85+ Study. *The Journals of Gerontology: Series A*, 73, 1258-1264.
- MILLER, J. W., BERESFORD, S. A., NEUHOUSER, M. L., CHENG, T.-Y. D., SONG, X., BROWN, E. C., ZHENG, Y., RODRIGUEZ, B., GREEN, R. & ULRICH, C. M. 2013. Homocysteine, cysteine, and risk of incident colorectal cancer in the Women's Health Initiative observational cohort. *The American journal of clinical nutrition*, 97, 827-834.
- MORIMOTO, Y., TAKAHASHI, H., ARITA, A., ITAKURA, H., FUJII, M., SEKIDO, Y., HATA, T., FUJINO, S., OGINO, T. & MIYOSHI, N. 2022. High postoperative carcinoembryonic antigen as an indicator of high-risk stage II colon cancer. *Oncology letters*, 23, 1-8.
- MÜHL, D., HEROLD, M., HEROLD, Z., HORNYÁK, L., SZASZ, A. M. & DANK, M. 2022. Longitudinal Analysis of 1 α , 25-dihydroxyvitamin D3 and Homocysteine Changes in Colorectal Cancer. *Cancers*, 14, 658.
- PHILIP, J. M., DUCROS, V., FAUCHERON, J. L., FLOURIE, B. & ROBLIN, X. 2008. Association of hyperhomocysteinemia and folate deficiency with colon tumors in patients with inflammatory bowel disease. *Inflammatory bowel diseases*, 14, 242-248.
- SUNG, H., FERLAY, J., SIEGEL, R. L., LAVERSANNE, M., SOERJOMATARAM, I., JEMAL, A. & BRAY, F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 71, 209-249.
- TARASIUK, A., MOSIŃSKA, P. & FICHNA, J. 2018. The mechanisms linking obesity to colon cancer: An overview. *Obesity research & clinical practice*, 12, 251-259.
- TORRE, L. A., BRAY, F., SIEGEL, R. L., FERLAY, J., LORTET-TIEULENT, J. & JEMAL, A. 2015. Global cancer statistics, 2012. *CA: a cancer journal for clinicians*, 65, 87-108.
- VAUGHAN-SHAW, P. G., BUIJS, L. F., BLACKMUR, J. P., THEODORATOU, E., ZGAGA, L., DIN, F. V., FARRINGTON, S. M. & DUNLOP, M. G. 2020. The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials. *British journal of cancer*, 123, 1705-1712.
- ZHANG, X.-H., MA, J., SMITH-WARNER, S. A., LEE, J. E. & GIOVANNUCCI, E. 2013. Vitamin B6 and colorectal cancer: current evidence and future directions. *World journal of gastroenterology: WJG*, 19, 1005.
- ZHOU, X., CHEN, C., ZHONG, Y. N., ZHAO, F., HAO, Z., XU, Y., LAI, R., SHEN, G. & YIN, X. 2020. Effect and mechanism of vitamin D on the development of colorectal cancer based on intestinal flora disorder. *Journal of gastroenterology and hepatology*, 35, 1023-1031.